HTB

Conference reports

IAS COVID-19 Conference: introduction

Conference opening and making sense of the science

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

AIDS 2020 online: introduction

AIDS 2020: Navigating the website

Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study

Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS 

ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau

Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes

Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART

Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083

Case report of short-term HIV remission from adding oral nicotinamide to intensified ART

New HIV remission case report at AIDS 2020: full report

23rd International AIDS Conference (AIDS 2020)

Conference on Retroviruses and Opportunistic Infections (CROI 2020)

Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial

A step forward for AAV-mediated delivery of bNAbs

10th International Workshop of HIV & Women

No neural tube defects among pregnancies with periconception dolutegravir exposure in the Dolomite-EPPICC cohort study

Conference on Retroviruses and Opportunistic Infections (CROI 2020)

CROI 2020: Special session on COVID-19

Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally

Long-acting cabotegravir and rilpivirine injections support two-monthly dosing

Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing

First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance

Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial

Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women

London patient is second person to be cured of HIV from allogeneic stem-cell transplant

The London Patient tells his story as second person cured of HIV

17th European AIDS Conference (EACS 2019)

Long-acting cabotegravir and rilpivirine: similar results in women and men 

Antiretroviral pregnancy registry: dolutegravir update

Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis

No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP

17th European AIDS Conference (EACS 2019)

Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV

Dolutegravir/lamivudine as dual ART

Weight changes with doravirine-based first line therapy

Bone and renal changes in the ADVANCE trial

10th International Workshop on HIV and Ageing

Featured Impact of isolation and loneliness on older people living with HIV

17th European AIDS Conference (EACS 2019)

EACS launch major update to European Treatment Guidelines (November 2019)

Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial

10th International Workshop on HIV and Ageing

Frailty in HIV care and the importance of lifestyle changes

Research into use of medicinal cannabis in HIV management

Vaping can help HIV positive smokers who are not motivated to quit cigarettes

IDWeek (2019), 2–6 October 2019, Washington DC

HIV suppression and safety with ibalizumab at 48 weeks in expanded access

Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study

Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available

Switching from TDF to TAF linked to higher BMI and cardio risk

Possible higher diabetes risk with raltegravir or PIs than NNRTIs

Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives

Over half of mostly black US HIV group has NAFLD – and many have NASH

People taking more medications and women have higher fall risk in older HIV group

No link between raltegravir and adverse birth outcomes in analysis in 2550 women

PrEP linked to lower HIV incidence in US, independent of TasP

10th IAS Conference on HIV Science (IAS 2019): final reports

Low rates of pregnancy with three methods of contraception in the ECHO trial

Other pregnancy studies IAS 2019

10th IAS Conference on HIV Science (IAS 2019) in Mexico City

Post navigation